Drug updated on 10/28/2024
Dosage Form | Injection (intravenous; 5 mg/2 mL [2.5 mg/mL], 10 mg/4 mL [2.5 mg/mL]) |
Drug Class | Dopamine-2 (D2) antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adults for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class
- Indicated in adults for treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Latest News
Summary
- This summary is based on the review of seven systematic review(s)/meta-analysis(es). [1-7]
- Amisulpride demonstrated significant effectiveness in preventing postoperative nausea and vomiting (PONV), with a 24-hour complete response rate (no emesis and no rescue antiemetic use) relative risk (RR) of 1.30 (95% CI (confidence interval): 1.20-1.41), particularly at a 5 mg dose (RR: 1.28, 95% CI: 1.18-1.39).
- In treating depressive symptoms in major psychiatric disorders, amisulpride at 50 mg/day showed greater symptom reduction compared to placebo (SMD (standardized mean difference) = -0.70, 95% CI: -0.92, -0.49), and it was comparable in efficacy to SSRIs and tricyclic antidepressants in the treatment of dysthymia.
- Amisulpride showed a significantly higher rate of intolerability-related discontinuations in monotherapy for major depressive disorder (MDD) compared to placebo.
- In postoperative nausea and vomiting (PONV) prevention, the adverse event profile of amisulpride was generally similar to placebo.
- The reviewed studies provide information on population types relevant to schizophrenia treatment (patients with sleep-related adverse effects), antidepressant-induced apathy (patients receiving SSRIs), major depressive disorder (adults receiving monotherapy or adjunctive antipsychotic therapy), and postoperative nausea and vomiting (adults undergoing surgery with general anesthesia).
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Barhemsys (amisulpride) Prescribing Information. | 2022 | Acacia Pharma, Inc., Indianapolis, IN |